Sustainability // HUTCHMED

This Report gives an annual update of HUTCHMED’s sustainability performance during 2021, including a comprehensive account of HUTCHMED's sustainability management approaches over topics identified as material to HUTCHMED's business and stakeholders relating to the operations of the two segments: (1) Oncology/Immunology and (2) Other Ventures.

Details of our corporate governance principles are contained in the Corporate Governance Report within our 2021 Annual Report.

Reporting Framework: This Report has been prepared in accordance with the provisions of the ESG Reporting Guide (Main Board Listing Rules Appendix 27) (“ESG Guide”) issued by The Stock Exchange of Hong Kong Limited (“HKEX”), and with reference to the Nasdaq ESG Reporting Guide, the London Stock Exchange Group's ESG Reporting Guidance, as well as mapped against the United Nations Sustainable Development Goals (“SDGs”).

Business ethics, including staff and partner awareness
Drug research-related topics, including animal welfare and intellectual property
Drug development-related topics, including clinical trial safety and personal data privacy and security
Commercial operations responsibilities, including quality, safety and traceability; patient monitoring and reporting; responsible marketing; and fair access of drugs
Environmental topics including waste and emissions
Management of our people, including talent acquisition, retention, development and engagement; occupational health and safety; and community investment.

	Unit	Oncology/Immunology & Hutchison Sinopharm (consolidated entities)	SHPL (non-consolidated joint venture)	Combined Total
Revenue ^{Note 1}	US$'000	334,388	332,648	667,036
Employee	person	1,715	2,883	4,598
GHG emissions (tCO₂e)
Total Emissions	tCO₂e	7,029	14,476	21,505
Direct GHG emissions (Scope 1)	tCO₂e	313	4,856	5,169
Indirect GHG emissions (Scope 2)	tCO₂e	6,716	9,620	16,336
Total GHG emission intensity (Scope 1 & 2) ^{Note 1}	tCO₂e per US$ ’000 revenue	0.021	0.044	0.032
Total GHG emission intensity (Scope 1 & 2) ^{Note 1}	tCO₂e per employee	4.10	5.02	4.68
Air emissions
Nitrogen Oxides (NOx)	kg	5.38	879	884
Sulphur Oxides (SOx)	Kg	0.12	0.33	0.45
Particulate Matter (PM)	Kg	0.40	155	155
Total energy Consumption
Total Energy Consumption	GJ	41,439	184,110	225,549
Electricity Consumption	GJ	41,140	58,743	99,883
Steam consumption	GJ	11	0	11
Natural gas consumption	GJ	0	124,587	124,587
Diesel consumption	GJ	0	2	2
Gasoline consumption	GJ	288	779	1,067
Total energy intensity ^{Note 1}	GJ/US$'000 revenue	0.124	0.553	0.338

tCO₂e = tonnes (metric tons, t) of carbon dioxide (CO₂) equivalent (e). GJ = Giga Joule (GJ), which is equal to 1 x 10⁹ joule (J).
Note 1: Revised on June 15, 2022 owing to revised segment revenue figures.

GHG emissions (Combined)

GHG emissions (tCO₂e)	2021	2020	Change (%)
Total emissions (tCO₂e)	21,505	21,946	-2%
Direct GHG emission (Scope 1)	5,169	6,040	-14%
Indirect GHG emission (Scope 2)	16,336	15,906	3%
Total GHG emission intensity (tCO₂e)/ US$'000 revenue ^{Note 1}	0.032	0.046	-30%
Total GHG emission intensity (tCO₂e) / employee	4.68	5.30	-12%

tCO₂e = tonnes (metric tons, t) of carbon dioxide (CO₂) equivalent (e)
Note 1: Revised on June 15, 2022 owing to revised segment revenue figures.

2021 Sustainability Report

About This Report

HUTCHMED’s Material Topics

Sustainability-related Policies

Key Environmental Data 2021

GHG emissions (Combined)

Sustainable Development Goals

Previous Reports